Measurable residual disease (MRD) is a critical diagnostic tool that predicts disease progression and is increasingly used as an important end point to monitor disease status and evaluate novel ...

This content is provided by an external author without editing by Finextra. It expresses the views and opinions of the author. Carreker and World-Check will offer a comprehensive enterprise-level ...

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...

UK-based biotech Charm Therapeutics has closed an oversubscribed Series B funding round worth $80m, which will support the progression of its acute myeloid leukaemia (AML) menin inhibitor into ...